Last checked at 
31 May 2024 13:57
Verici Dx plc
("Verici Dx" or the "Company")
Posting of Annual Report & Accounts
andNotice of Annual General Meeting
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, confirms that the Annual Report and Accounts for the year ended 31 December 2023 ("2023 Annual Report") and the Notice of the 2024 Annual General Meeting ("AGM") have now been published on the Company's website vericidx.com/investors/.
The 2023 Annual Report, the Notice of AGM and details for voting by proxy will be posted to shareholders who have not consented to receive electronic communications today, on 31 May 2024.
The AGM is to be held on 25 June 2024 at 11.30 a.m. at Shoosmiths LLP, No. 1 Bow Churchyard, London EC4M 9DQ and will consider the Resolutions set out in the Notice of AGM.
Proxy voting
Shareholders will not receive a hard copy form of proxy for the AGM in the post. Instead, shareholders will be able to vote electronically using the link www.signalshares.com. Proxy votes must be received no later than 11.30 a.m. on 21 June 2024.
Shareholders may request a hard copy form of proxy directly from the Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales. Alternatively, shareholders can vote by downloading the new app, LinkVote+, on Apple App Store or Google Play and following the instructions.
Enquiries:
Verici Dx | www.vericidx.com |
Sara Barrington, CEO | investors@vericidx.com |
Julian Baines, Chairman |
|
|
|
Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 20 7496 3000 |
Aubrey Powell / Sam Butcher | |
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
